Vaccines Give Sanofi, Glaxo a Shot of Optimism as Views Raised
Photographer: Sanjit Das/Bloomberg
This article is for subscribers only.
Vaccines are putting some pep into big drugmakers’ profits.
Sanofi and GlaxoSmithKline Plc each raised their annual forecasts, based in part on brisk sales of the preventive drugs. Glaxo cited better-than-expected sales of its Shingrix shot, while Sanofi credited vaccines along with its up-and-coming Dupixent drug for eczema.